Literature DB >> 18077788

Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality.

Lisa K Jasperson1, Christoph Bucher, Angela Panoskaltsis-Mortari, Patricia A Taylor, Andrew L Mellor, David H Munn, Bruce R Blazar.   

Abstract

Graft-versus-host disease (GVHD) is initiated after activation of donor T cells by host antigen-presenting cells (APCs). The immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) is expressed by APCs and parenchymal cells and is further inducible by inflammation. We investigated whether lethal conditioning and GVHD induce IDO and if IDO prevents tissue injury by suppressing immune responses at the induction site. We determined that IDO is a critical regulator of GVHD, most strikingly in the colon, where epithelial cells dramatically up-regulated IDO expression during GVHD. IDO(-/-) mice died more quickly from GVHD, displaying increased colonic inflammation and T-cell infiltration. GVHD protection was not mediated by control of T-cell proliferation, apoptosis, or effector mechanisms in lymphoid organs, nor did it require donor T regulatory cells. Instead, T cells in IDO(-/-) colons underwent increased proliferation and decreased apoptosis compared with their wild-type counterparts. This evidence suggests that IDO can act at the site of expression to decrease T-cell proliferation and survival, diminishing colonic inflammation and reducing disease severity. These studies are the first to identify a function for IDO in GVHD lethality and indicate that modulation of the IDO pathway may be an effective strategy for treatment of this disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18077788      PMCID: PMC2265461          DOI: 10.1182/blood-2007-06-096081

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

1.  Indoleamine 2,3-dioxygenase expression in patients with acute graft-versus-host disease after allogeneic stem cell transplantation and in pregnant women: association with the induction of allogeneic immune tolerance?

Authors:  N K Steckel; U Kuhn; D W Beelen; A H Elmaagacli
Journal:  Scand J Immunol       Date:  2003-02       Impact factor: 3.487

2.  Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses.

Authors:  Andrew L Mellor; Derin B Keskin; Theodore Johnson; Phillip Chandler; David H Munn
Journal:  J Immunol       Date:  2002-04-15       Impact factor: 5.422

3.  T cell apoptosis by tryptophan catabolism.

Authors:  F Fallarino; U Grohmann; C Vacca; R Bianchi; C Orabona; A Spreca; M C Fioretti; P Puccetti
Journal:  Cell Death Differ       Date:  2002-10       Impact factor: 15.828

4.  Inhibition of experimental asthma by indoleamine 2,3-dioxygenase.

Authors:  Tomoko Hayashi; Lucinda Beck; Cyprian Rossetto; Xing Gong; Osamu Takikawa; Kenji Takabayashi; David H Broide; Dennis A Carson; Eyal Raz
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

5.  Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice.

Authors:  Gregory J Gurtner; Rodney D Newberry; Suzanne R Schloemann; Keely G McDonald; William F Stenson
Journal:  Gastroenterology       Date:  2003-12       Impact factor: 22.682

6.  In vivo imaging of graft-versus-host-disease in mice.

Authors:  Angela Panoskaltsis-Mortari; Andrew Price; John R Hermanson; Elizabeth Taras; Chris Lees; Jonathan S Serody; Bruce R Blazar
Journal:  Blood       Date:  2004-01-08       Impact factor: 22.113

7.  Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific.

Authors:  Babak Baban; Phillip Chandler; Doris McCool; Brendan Marshall; David H Munn; Andrew L Mellor
Journal:  J Reprod Immunol       Date:  2004-04       Impact factor: 4.054

8.  CDllc+ cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenase.

Authors:  Kena A Swanson; Yan Zheng; Kathleen M Heidler; Teruaki Mizobuchi; David S Wilkes
Journal:  Am J Respir Cell Mol Biol       Date:  2003-09-04       Impact factor: 6.914

9.  Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells.

Authors:  David H Munn; Madhav D Sharma; Andrew L Mellor
Journal:  J Immunol       Date:  2004-04-01       Impact factor: 5.422

10.  Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion.

Authors:  Andrew L Mellor; Babak Baban; Phillip Chandler; Brendan Marshall; Kanchan Jhaver; Anna Hansen; Pandelakis A Koni; Makio Iwashima; David H Munn
Journal:  J Immunol       Date:  2003-08-15       Impact factor: 5.422

View more
  72 in total

Review 1.  Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.

Authors:  Elizabeth O Stenger; Hēth R Turnquist; Markus Y Mapara; Angus W Thomson
Journal:  Blood       Date:  2012-03-07       Impact factor: 22.113

2.  IDO in human gut graft-versus-host disease.

Authors:  Philippe Ratajczak; Anne Janin; Régis Peffault de Larour; Lisa Koch; Brigitte Roche; David Munn; Bruce R Blazar; Gérard Socié
Journal:  Biol Blood Marrow Transplant       Date:  2011-08-09       Impact factor: 5.742

3.  Attenuation of acute graft-versus-host disease in the absence of the transcription factor RORγt.

Authors:  LeShara M Fulton; Michael J Carlson; James M Coghill; Laura E Ott; Michelle L West; Angela Panoskaltsis-Mortari; Dan R Littman; Bruce R Blazar; Jonathan S Serody
Journal:  J Immunol       Date:  2012-07-09       Impact factor: 5.422

4.  In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines.

Authors:  K L Hippen; R S O'Connor; A M Lemire; A Saha; E A Hanse; N C Tennis; S C Merkel; A Kelekar; J L Riley; B L Levine; C H June; L A Turka; L S Kean; M L MacMillan; J S Miller; J E Wagner; D H Munn; B R Blazar
Journal:  Am J Transplant       Date:  2017-06-14       Impact factor: 8.086

Review 5.  Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new.

Authors:  James M Coghill; Stefanie Sarantopoulos; Timothy P Moran; William J Murphy; Bruce R Blazar; Jonathan S Serody
Journal:  Blood       Date:  2011-01-18       Impact factor: 22.113

6.  Constitutively active Stat5b in CD4+ T cells inhibits graft-versus-host disease lethality associated with increased regulatory T-cell potency and decreased T effector cell responses.

Authors:  Christine Vogtenhuber; Christoph Bucher; Steven L Highfill; Lisa K Koch; Emily Goren; Angela Panoskaltsis-Mortari; Patricia A Taylor; Michael A Farrar; Bruce R Blazar
Journal:  Blood       Date:  2010-05-04       Impact factor: 22.113

Review 7.  Concise review: hitting the right spot with mesenchymal stromal cells.

Authors:  Jakub Tolar; Katarina Le Blanc; Armand Keating; Bruce R Blazar
Journal:  Stem Cells       Date:  2010-08       Impact factor: 6.277

8.  Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice.

Authors:  Pavan Reddy; Yaping Sun; Tomomi Toubai; Raimon Duran-Struuck; Shawn G Clouthier; Elizabeth Weisiger; Yoshinobu Maeda; Isao Tawara; Oleg Krijanovski; Erin Gatza; Chen Liu; Chelsea Malter; Paolo Mascagni; Charles A Dinarello; James L M Ferrara
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

Review 9.  Hypoxia and Mucosal Inflammation.

Authors:  Sean P Colgan; Eric L Campbell; Douglas J Kominsky
Journal:  Annu Rev Pathol       Date:  2016-05-23       Impact factor: 23.472

Review 10.  IDO: a double-edged sword for T(H)1/T(H)2 regulation.

Authors:  Hui Xu; Guang-Xian Zhang; Bogoljub Ciric; Abdolmohamad Rostami
Journal:  Immunol Lett       Date:  2008-09-29       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.